Innate Immune Cells in Non-Small Cell Lung Cancer: Roles in Tumor Progression and Therapeutic Responses [0.03%]
非小细胞肺癌中的固有免疫细胞：在肿瘤进展和治疗反应中的作用
Jiaxin Liu,Jie Jia,Chong Wang et al.
Jiaxin Liu et al.
As a leading cause of cancer-related morbidity and mortality worldwide, non-small cell lung cancer (NSCLC) is profoundly influenced by innate immune cells (IICs). In addition to serving as key mediators of antimicrobial defense and adaptive...
Low-Dose Antiangiogenic Therapy With Different Chemotherapy Backbones Among Patients With Heavily Pretreated Metastatic Breast Cancer [0.03%]
低剂量抗血管生成疗法联合不同化疗 backbone 治疗广泛预处理的转移性乳腺癌患者
Yuanyi Wang,Yalong Qi,Cheng Zeng et al.
Yuanyi Wang et al.
Background: The prognosis for metastatic breast cancer (MBC) remains poor, and treatment options are limited for patients with heavily pretreated disease. Although antiangiogenic agents may provide clinical benefit in thi...
Katherine Yaacoub
Katherine Yaacoub
When cells are unable to maintain their proper functions, they go into "Cell Death", either "Accidental" which is uncontrolled, or "Regulated" which is programmed and involves signaling cascades of specific molecules. Any perturbation of th...
Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials [0.03%]
妇科肿瘤治疗进展：近期临床试验的启示
Yiyang Shen,Xiaofei Jiao,Yuanjia Wen et al.
Yiyang Shen et al.
Gynecologic cancers remain a major global health burden for women. Their management has evolved toward a gynecologic oncologist-led multimodal paradigm. While these approaches have improved outcomes, critical limitations persist, including ...
Practice-Changing Advances in Systemic Therapies Shaping the Landscape of Lung Cancer in 2025 [0.03%]
有望重塑2025年肺癌治疗格局的系统性疗法实践改变型进展
Zhenyu Zhou,Wanting Gao,Molly S C Li et al.
Zhenyu Zhou et al.
With the rapid advancement of molecular profiling and precision therapeutics, targeted and immunotherapeutic strategies have irrevocably reshaped the pharmacological management for both non-small cell lung cancer (NSCLC) and small cell lung...
Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition) [0.03%]
中国乳腺癌PARPs抑制剂临床应用专家共识（2025版）
Fei Ma,Binghe Xu;China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs et al.
Fei Ma et al.
Breast cancer represents a major threat to women's health in China. Its continuously rising incidence contributes to a growing disease burden, thereby creating a critical demand for novel and effective therapeutic strategies. In recent year...
Constructing Tumor Cellular Cluster Models and Their Evolutionary Dynamics to Decode Tumor Evolution [0.03%]
构造肿瘤细胞群模型及其进化动力学以解码肿瘤进化
Haili Qian,Fei Ma
Haili Qian
Multiple Primary Malignancies in Patients With Gastric Cancer: A Retrospective Study in National Cancer Center of China [0.03%]
中国国家癌症中心胃癌患者的多原发恶性肿瘤的回顾性研究
Guiling Zhu,Yutong Li,Bingzhi Wang et al.
Guiling Zhu et al.
Background: Gastric cancer (GC) is a prevalent malignancy in China, posing significant health challenges. The persistently high tumor incidence and the rising number of tumor survivors may elevate the risk of multiple pri...
Rationale and Trial Design of DAWNA-FES Trial: Single-Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2- Advanced Breast Cancer [0.03%]
DAWNA-FES研究的 rationale与试验设计：HR+/HER2-晚期乳腺癌患者CDK4/6抑制剂进展后基于[18F]FES PET/CT的达尔贝泊利单药治疗Ⅱ期临床研究方案
Ru Yao,Yang Qu,Zhixin Hao et al.
Ru Yao et al.
Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have become a cornerstone in the first-line management of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breas...